Terms: = Sarcomas AND CDK6, MGC59692, 1021, Q00534, ENSG00000105810, PLSTIRE AND Prognosis
15 results:
1. Development of a novel six DNA damage response-related prognostic signature in osteosarcoma.
Li T; Tang Z; Li S; Lu M
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):110-115. PubMed ID: 38650147
[TBL] [Abstract] [Full Text] [Related]
2. Vitexicarpin Induces Apoptosis and Inhibits Metastatic Properties via the AKT-PRAS40 Pathway in Human Osteosarcoma.
Yun HM; Kwon HS; Lee JY; Park KR
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612399
[TBL] [Abstract] [Full Text] [Related]
3. The Targeted Therapies for Osteosarcoma
Wang S; Ren Q; Li G; Zhao X; Zhao X; Zhang Z
Curr Mol Pharmacol; 2024; 17(1):e210823220109. PubMed ID: 37602543
[TBL] [Abstract] [Full Text] [Related]
4. CRISPR-Cas9 screening identified lethal genes enriched in necroptosis pathway and of prognosis significance in osteosarcoma.
Cheng L; Xiong W; Li S; Wang G; Zhou J; Li H
J Gene Med; 2023 Dec; 25(12):e3563. PubMed ID: 37421290
[TBL] [Abstract] [Full Text] [Related]
5. A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy.
Pan R; Pan F; Zeng Z; Lei S; Yang Y; Yang Y; Hu C; Chen H; Tian X
Front Immunol; 2022; 13():1017120. PubMed ID: 36189307
[TBL] [Abstract] [Full Text] [Related]
6. Oncogenic lncRNA ZNFX1 antisense RNA 1 promotes osteosarcoma cells proliferation and metastasis by stabilizing serine and arginine‑rich splicing factor 3.
Zhang Y; Xu W; Wang Y; Li J; He G; Guan M; Zeng X; Bian W; Song Y; Liu J
Bioengineered; 2022 Mar; 13(3):5962-5974. PubMed ID: 35184675
[TBL] [Abstract] [Full Text] [Related]
7. Downregulated Long Non-Coding RNA MSC-AS1 Inhibits Osteosarcoma Progression and Increases Sensitivity to Cisplatin by Binding to MicroRNA-142.
Zhang L; Zhao G; Ji S; Yuan Q; Zhou H
Med Sci Monit; 2020 Mar; 26():e921594. PubMed ID: 32155139
[TBL] [Abstract] [Full Text] [Related]
8. Long intergenic non‑protein coding RNA 00460 predicts a poor prognosis and promotes tumorigenesis of human osteosarcoma.
Jiang JJ; Wang FC; Han LP
Mol Med Rep; 2020 Feb; 21(2):649-658. PubMed ID: 31974626
[TBL] [Abstract] [Full Text] [Related]
9. Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study.
Korach J; Colombo N; Mendiola C; Selle F; Dolado I; Donica M; Oza AM
J Surg Oncol; 2019 Sep; 120(4):786-793. PubMed ID: 31368160
[TBL] [Abstract] [Full Text] [Related]
10. Long Noncoding RNA SNHG7 Promotes the Tumor Growth and Epithelial-to-Mesenchymal Transition via Regulation of miR-34a Signals in Osteosarcoma.
Deng Y; Zhao F; Zhang Z; Sun F; Wang M
Cancer Biother Radiopharm; 2018 Nov; 33(9):365-372. PubMed ID: 29989838
[TBL] [Abstract] [Full Text] [Related]
11. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract] [Full Text] [Related]
12. In vitro and in vivo anti-primary effusion lymphoma activities of fucoidan extracted from Cladosiphon okamuranus Tokida.
Ishikawa C; Mori N
Oncol Rep; 2017 Nov; 38(5):3197-3204. PubMed ID: 29048633
[TBL] [Abstract] [Full Text] [Related]
13. MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, cdk6.
Li Y; Liu J; Liu ZZ; Wei WB
Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5117-5125. PubMed ID: 28051259
[TBL] [Abstract] [Full Text] [Related]
14. Current Status of Biological Therapies for the Treatment of Metastatic Melanoma.
Tang T; Eldabaje R; Yang L
Anticancer Res; 2016 Jul; 36(7):3229-41. PubMed ID: 27354579
[TBL] [Abstract] [Full Text] [Related]
15. [Clinicopathologic features of pleomorphic rhabdomyosarcoma].
Yu L; Wang J
Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):147-52. PubMed ID: 23769431
[TBL] [Abstract] [Full Text] [Related]
